LIFT: Sodium zirconium cyclosilicate doubled the share of HFrEF patients with CKD reaching target RAASi dose without hyperkalemia (2026) — Trial Summary
LIFT: Sodium zirconium cyclosilicate doubled the share of HFrEF patients with CKD reaching target RAASi dose without hyperkalemia (2026): Double-blind, placebo-controlled randomized trial in patients with heart failure with reduced ejection fraction, CKD stages 3-5, and serum potassium 5.0 to 5.5 mm
References
- Banerjee D, Ali M, Tumelty E, Murphy D, Warrens H, Parmar S, et al. Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial. Nat Commun. 2026;17(1):11614. doi:10.1038/s41467-026-78377-0